Dr. Brian Michael Morrissey, MD

Dr. Morrissey practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Dr. Morrissey's NPI, 1992780209, was assigned on December 8, 2005. Dr. Morrissey graduated from Saint Louis University School of Medicine in 1993. Dr. Morrissey holds California license G079546.

Dr. Morrissey's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Dr. Morrissey's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. Dr. Morrissey is also affiliated with Enloe Health. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Morrissey to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Morrissey practices, 3 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Morrissey's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Morrissey is licensed in California.

CMS data shows 1,051 Medicare services from Dr. Morrissey across 15 procedure codes in 2024, for 436 Medicare patients. Medicare paid $49,793 for them.

CMS counts 436 Medicare patients who saw Dr. Morrissey in 2024. The largest group is 75 to 84, with 172 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 29% are also on Medicaid. Their average risk score is 2.67, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Morrissey's median patient age at 56, with 53% women.

In 2024, Dr. Morrissey wrote 720 Medicare Part D claims for 71 patients. 31% of them were for generic drugs. CMS names the drug for 590 of them, across 21 drugs with 11 or more claims each, at $4,421,758 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Morrissey for performance year 2024, reported as part of a group. Dr. Morrissey accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Morrissey as offering telehealth.

Dmand AI links 20 papers to Dr. Morrissey, published from 2010 to 2022. 2012 was the busiest year, with 4. The most frequent topics are Tandem Mass Spectrometry, Biomarkers, Tumor and Blood Proteins. Dr. Morrissey's most frequent co-authors are Carroll E. Cross, MD, Timothy Eugene Albertson, MD, MPH, PhD and Mark Velimir Avdalovic, MD.

Dmand AI links Dr. Morrissey to 8 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Cystic Fibrosis, Inflammation and alpha 1-Antitrypsin Deficiency. Laurent Pharmaceuticals Inc. sponsors the most, 2. Open Payments lists research payments to Dr. Morrissey that name 1 trial.

CMS Open Payments shows 38 general payments to Dr. Morrissey from 2 drug and device companies from 2024 to 2025. Consulting fees make up the largest share, 85% of the total. Insmed, Inc. paid the most, $40,811. It also lists 12 research payments totaling $1,463 in 2024, naming 1 clinical trial.

Dr. Morrissey graduated from Saint Louis University School of Medicine in 1993.